Clinical Trial Update: Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) [Phase 2, Phase 3]

View source ↗

Summary

Study evaluating camrelizumab plus chemotherapy as neoadjuvant therapy for triple negative breast cancer across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Triple Negative Breast Cancer | Phase 2, Phase 3 | Status: UNKNOWN